Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Inventory Average (2016 - 2025)

Historic Inventory Average for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to $13.7 million.

  • Ligand Pharmaceuticals' Inventory Average fell 2265.62% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year decrease of 2265.62%. This contributed to the annual value of $19.0 million for FY2024, which is 220.06% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Inventory Average is $13.7 million, which was down 2265.62% from $15.1 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Inventory Average registered a high of $38.4 million during Q2 2021, and its lowest value of $13.7 million during Q1 2023.
  • For the 5-year period, Ligand Pharmaceuticals' Inventory Average averaged around $22.8 million, with its median value being $22.7 million (2024).
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Inventory Average soared by 59749.59% in 2021, and later tumbled by 4842.27% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Inventory Average (Quarter) stood at $30.2 million in 2021, then plummeted by 40.95% to $17.8 million in 2022, then surged by 38.58% to $24.7 million in 2023, then tumbled by 37.49% to $15.4 million in 2024, then fell by 11.23% to $13.7 million in 2025.
  • Its Inventory Average stands at $13.7 million for Q3 2025, versus $15.1 million for Q2 2025 and $14.4 million for Q1 2025.